Trial · NCT07897097
Study on the Mechanism of Central Obesity Induced by Sleep Restriction and the Therapeutic Effect of n-3 Polyunsaturated Fatty Acid: a Randomized, Double-blind, Placebo-controlled Trial (COSPA Study)
NCT07897097, Not applicable, Not yet recruiting, Beijing Anzhen Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study on the Mechanism of Central Obesity Induced by Sleep Restriction and the Therapeutic Effect of n-3 Polyunsaturated Fatty Acid: a Randomized, Double-blind, Placebo-controlled Trial (COSPA Study). Trials, record NCT07897097. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897097
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study on the Mechanism of Central Obesity Induced by Sleep Restriction and the Therapeutic Effect of n-3 Polyunsaturated Fatty Acid: a Randomized, Double-blind, Placebo-controlled Trial (COSPA Study)
- NCT number
- NCT07897097
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Beijing Anzhen Hospital
- Conditions
- Sleep Deprivation
- Interventions
- n-3 PUFA Supplementation, Placebo Supplementation, Experimental Sleep Restriction
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes47
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Visceral Adipose Tissue Area | Day 3 (T1) and Day 17 (T2) | Change in abdominal visceral adipose tissue area measured by CT, calculated as the value on Day 17 minus the value on Day 3, expressed in cm². |
| Secondary | Change in Subcutaneous Adipose Tissue Area | Day 3 (T1) and Day 17 (T2) | Change in abdominal subcutaneous adipose tissue (SAT) area measured by CT, calculated as SAT area on Day 17 minus SAT area on Day 3 (ΔSAT), expressed in cm² |
| Secondary | Change in Total Abdominal Adipose Tissue Area | Day 3 (T1) and Day 17 (T2) | Change in total abdominal adipose tissue (TAT) area measured by CT, calculated as TAT area on Day 17 minus TAT area on Day 3 (ΔTAT), expressed in cm² |
| Secondary | Change in Visceral-to-Subcutaneous Adipose Tissue Ratio | Day 3 (T1) and Day 17 (T2) | Change in the ratio of visceral to subcutaneous adipose tissue area (VAT/SAT), calculated as the ratio on Day 17 minus the ratio on Day 3 |
| Secondary | Changes in Gut Microbial Alpha Diversity (Shannon Index) | 8 weeks before the residential phase (T0), Day 3 (T1), Day 10, and Day 17 (T2) | Changes in fecal gut microbial alpha diversity measured by the Shannon diversity index using 16S rRNA gene sequencing. Shannon index values reflect microbial richness and evenness and are unitless. |
| Secondary | Changes in Gut Microbial Beta Diversity (Bray-Curtis Dissimilarity) | 8 weeks before the residential phase (T0), Day 3 (T1), Day 10, and Day 17 (T2) | Changes in gut microbial community composition assessed using Bray-Curtis dissimilarity based on 16S rRNA gene sequencing data. Between-sample differences will be evaluated using PERMANOVA. |
| Secondary | Changes in Gut Microbial Taxonomic Abundance | 8 weeks before the residential phase (T0), Day 3 (T1), Day 10, and Day 17 (T2) | Changes in the relative abundance of gut microbial taxa assessed by fecal microbiome sequencing and differential abundance analysis |
| Secondary | Changes in Fecal Short-Chain Fatty Acid Concentrations | 8 weeks before the residential phase (T0), Day 3 (T1), Day 10, and Day 17 (T2) | Changes in fecal short-chain fatty acid concentrations, including acetate, propionate, and butyrate, assessed using metabolomic methods. |
| Secondary | Changes in High-Sensitivity C-Reactive Protein Levels | 8 weeks before the residential phase (T0), Day 3 (T1), Day 10, and Day 17 (T2) | Changes in serum or plasma hs-CRP concentrations measured across the study time points. |
| Secondary | Changes in Interleukin-6 Levels | 8 weeks before the residential phase (T0), Day 3 (T1), Day 10, and Day 17 (T2) | Changes in serum or plasma IL-6 concentrations measured across the study time points. |
1 to 10 of 47Source ClinicalTrials.gov
See all 47 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897097
GET https://conductscience.org/api/trials/v1/NCT07897097/registered?page=2